Skip to content

Detection of Saliva by Immunoaffinity and Mass Spectrometry

Detection of Specific Salivary Proteins by Immunoaffinity and Mass Spectrometry

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06183385
Acronym
SIMS
Enrollment
35
Registered
2023-12-27
Start date
2024-01-15
Completion date
2024-12-31
Last updated
2023-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sexual Assault

Keywords

saliva, proteins, biomarkers, mass spectrometry

Brief summary

The identification of saliva in genital area during a criminal investigation can be a critical component in the prosecution of a sexual assault in France, as non-consensual oral-genital intercourses have been considered as crimes since 2021.The development of highly specific methods for saliva detection is therefore crucial as the commonly employed screening methods lack specificity. Protein mass spectrometry has proven to be a sensitive and specific method but is particularly time consuming. A faster and more sensitive hybrid approach using automated immunoaffinity mass spectrometry (IP-LC-MS/MS) has been recently developed and has been found to be particularly performant for the detection of a seminal fluid protein (semenogelin), allowing a high-throughput seminal fluid identification in semen samples. Like semenogelin, specific salivary proteins such as histatin type 1, cystatin D or proline-rich proteins (PRPs) could be detected using this promising approach, which has never been tested on saliva samples. In collaboration with the Clinical Proteomics Platform and the Department of Reproductive Medicine of the University Hospital of Montpellier, we aim to develop a protocol for the detection of specific saliva proteins by IP-LC-MS/MS in sexual assault-type samples.

Detailed description

Each participant will be contacted by a phone call the day before the visit, to present for a presentation of the study.The day of the visit, two types of samples will be collected : * Saliva samples: on healthy volunteers in the Department of Legal Medicine (2 samples of 1.5 - 2 mL are collected for each volunteer). * Vaginal samples : on women consulting in the Department of Reproductive Medicine (2 dry swabs on each patient). 2 groups, One group with vaginal secretion fluid samples only, and one group with vaginal secretion fluid + sperm samples.

Interventions

OTHERSaliva collection

Collection of 2 samples of 1.5 to 2mL of saliva by passive salivation in healthy volunteers

OTHERVaginal secretion collection

Collection of vaginal secretions with 2 dry swabs in women

OTHERIP-LC-MS/MS : immunoprecipitation enrichment with liquid chromatography coupled to tandem mass spectrometry

sample preparation and analysis : * Impregnation of the tips (absorbent cotton) of sterile dry swabs and vaginal swabs with controlled quantities of saliva. * Immunocapture of salivary proteins of interest (histatin type 1, cystatin D, PRPs) by protein A affinity purification * LC-MS/MS analysis of eluted purified peptides (Multiple Reaction Monitoring mode) Dilutions will be made from 10 to 10 (1/10, 1/100, 1/1000...), then after reaching a detectability threshold, specified by a second more precise analysis (e.g. if no signal at 1/1000, analysis at 1/500 then 1/250 etc.). Analytical sensitivity will be tested on three samples of each type (salivary, vaginal, vaginal + semen) to ensure reproducibility of results. Operators, unaware of the presence of saliva in the samples, will then carry out saliva-specific protein detection analysis using the IP-LC-MS/MS method.

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Saliva Samples * Men and women aged 18 or more Vaginal samples : * Women aged 18 or more * No unprotected vaginal sexual intercourse during the 10 days prior to the visit (group 1) * Unprotected vaginal sexual intercourse with ejaculation in the 24 hours prior to the visit (group 2)

Exclusion criteria

Saliva Samples : * Active pathology of the saliva glands (infection, tumor) * Unprotected oral-genital sexual intercourse in the 24 hours prior to the visit * Failure to obtain written informed consent after a reflection period * Pregnant or breast feeding women * Adult protected by law or under guardianship or curatorship * No affiliation to the French Social Security System or no benefit from such a system Vaginal Samples : * Oral-genital sexual intercourse (cunnilingus) in the 24 hours prior to the visit * Failure to obtain written informed consent after a reflection period * Pregnant or Breastfeeding women * Adult protected by law or under guardianship or curatorship * No affiliation to the French Social Security System or no benefit from such a system

Design outcomes

Primary

MeasureTime frameDescription
Reproducibility between saliva samples3 monthsIntra-assessor agreement on saliva samples, which involves testing the first sample and retesting the second sample The study's primary endpoint will be to measure the reliability of the protocol, consisting of reproducibility or intra-assessor agreement,for the detection of specific salivary proteins (histatin type 1, PRPs, cystatin D) using the IP-LC-MS/MS method on adult saliva samples. Intra-assessor agreement (test/retest) will be measured by their means +/- standard deviation. Several analyses (between 3 or 4) on the same sample will be carried out to determine whether the results are identical
Intermediate fidelity between technicians on saliva samples3 monthsInter-assessor agreement(Cohen's kappa coefficient) on saliva samples, which involves testing several samples by at least 2 different technicians The study's primary endpoint will be to measure the reliability of the protocol, consisting of intermediate fidelity or inter-assessor agreement (Cohen's kappa coefficient) for the detection of specific salivary proteins (histatin type 1, PRPs, cystatin D) using the IP-LC-MS/MS method on adult saliva samples. The kappa coefficient gives a score ranging from 0 to 1. If the coders totally agree, κ = 1. If they totally disagree (or agree due solely to chance), κ ≤ 0.

Secondary

MeasureTime frameDescription
Analytical Sensibility3 monthsLowest saliva concentration (µL) detected by the method on saliva samples and on vaginal samples soaked with saliva in controlled condition
Reproducibility between vaginal samples soaked with saliva3 monthsIntra-assessor agreement on vaginal samples soaked with saliva The secondary endpoints, will consist of repeating the primary endpoints (i.e. reproducibility and intermediate fidelity) on the vaginal samples impregnated with sperm or not. Again, the same sample will be tested several times (between 3 or 4) to see if the results come back similar.
Diagnostic specificity3 monthsAnalysis of vaginal samples and dry samples in controlled condition, to determine the rate of false positives and true negatives.
Diagnostic sensibility3 monthsAnalysis of saliva samples and vaginal samples soaked with saliva in controlled condition, to determine the rate of detection of true positives and false negatives
Intermediate fidelity between technicians on vaginal samples soaked with saliva3 months: Inter-assessor agreement (Cohen's kappa coefficient) on vaginal samples soaked with saliva The secondary endpoints, will consist of repeating the primary endpoints (i.e. reproducibility and intermediate fidelity) on the vaginal samples impregnated with sperm or not. The kappa coefficient gives a score ranging from 0 to 1. If the coders totally agree, κ = 1. If they totally disagree (or agree due solely to chance), κ ≤ 0.

Countries

France

Contacts

Primary ContactPierre-Antoine PEYRON, PI
pa-peyron@chu-montpellier.fr04 67 33 85 86
Backup ContactLaëtitia LEVEQUE
l-leveque@chu-montpellier.fr04 67 33 85 86

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026